Search

everythinglearnresearchcommunity

for

Search:↓

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

Secukinumab for psoriasis may cause hair loss.

Cinacalcet may help treat hereditary vitamin D resistant rickets safely.

Certain mutations in the PADI3 gene may increase the risk of developing a type of scarring hair loss common in women of African descent.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

QLT0267 stops hair follicle cell growth and movement.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Baricitinib is the most effective treatment for alopecia areata.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Raltegravir may cause hair loss in some patients.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Tofacitinib treatment for hair loss may worsen acne.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.